Róisín Shortall (Dublin North West, Labour)

I thank Deputy Neville for raising this issue as it provides me with an opportunity to outline to the House its importance.

In response to the 2009 H1N1 influenza pandemic, the HSE procured two vaccines, Pandemrix from GlazoSmithKline and Celvapan from Baxter. The HSE, with the approval of the Departments of Health and Finance, indemnified the suppliers from and against loss and damage in respect of any claim. This was the arrangement for all European countries.

Following reports of an increased incidence of narcolepsy in young people who were vaccinated with the Pandemrix vaccine, the Department commissioned a retrospective population-based study to investigate a possible association. Last week the Minister, Deputy Reilly, published the findings of this study. The study concluded that the increased incidence of narcolepsy in young people may be associated with Pandemrix vaccine. The findings are similar to those found in Finland.

My Department is working closely with the Health Service Executive and the Department of Education and Skills to address the needs of those affected by this condition. A memorandum for Government setting out the full response to this issue is being prepared for submission in the coming weeks. I assure the House this matter is a priority for the Department and all possible options are being explored to meet the needs of those who developed narcolepsy following receipt of the pandemic vaccine. I thank the Deputy for raising the matter.

See this speech in context